CTOs on the Move


 
Sobi is an international specialty healthcare company dedicated to developing treatments and extensive patient support networks for people with rare and difficult to treat diseases. These patients are often misunderstood, misdiagnosed and have limited medical options otherwise. This commitment has led to our world-class capabilities in protein biochemistry and biologics manufacturing, recognized by our leading industry partners. In North America, we have established our home bases in Waltham, MA and Toronto, Canada. Our employees not only have deep expertise in rare diseases, but are also dedicated to listening and learning from patients, payers and HCPs to ensure we’re bringing value ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.sobi.com
  • 890 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.786.7370

Executives

Name Title Contact Details

Similar Companies

Cathay Industrial Biotech

Cathay Industrial Biotech is a Mt Zion, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alamar Biosciences

Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.

Takeda Oncology

Takeda Oncology,, is a biopharmaceutical company based in Cambridge, Massachusetts.

CereVasc

The CereVasc eShunt™ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.

Mersana

Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.